

altered C-terminal domain comprising a consensus SH3 binding site.

107. (New) A nucleic acid molecule encoding a human telomerase that lacks the C-terminal domain of the human telomerase presented in SEQ ID No. 2.

REMARKS

Claims 1-107 are pending in the instant application. Newly added claims 65-107 do not add new matter. Applicants respectfully request consideration of the new claims 65-107. Additionally, the enclosed Sequence Listing includes no new material, but merely adds sequence identifiers to the specification as required by 37 C.F.R. § 1.821(d), and bring this application into compliance with 37 C.F.R. §§ 1.821-1.825 and WIPO Standard 25. Allowance of this application is earnestly solicited.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:nr/rap

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

U:\cambia\71

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Present Application:

Applicants : Andrzej Kilian and David Bowtell
Title : VERTEBRATE TELOMERASE GENES AND PROTEINS AND
USES THEREOF
Docket No. : 190106.407C1
Date : February 11, 2000

Prior Application:

Examiner : Einar Stole, Ph.D.
Art Unit : 1653
Application No.: 09/108,401

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231


DECLARATION

Sir:

I, Lawrence Teague, in accordance with 37 C.F.R. § 1.821(f) do hereby declare that, to the best of my knowledge, the content of the paper entitled "Sequence Listing" enclosed herewith and the computer readable copy contained within the floppy disk filed in U.S. Patent Application Number 09/108,401 filed June 30, 1998, are the same.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated this 11th day of February, 2000.



Lawrence Teague
Biotechnology Paralegal

701 5th Ave, Suite 6300
Seattle, WA 98104-7092
(206) 622-4900
FAX (206) 682-6031